Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study
- PMID: 29174612
- DOI: 10.1016/S2352-3018(17)30206-0
Mortality and its determinants in antiretroviral treatment-naive HIV-infected children with suspected tuberculosis: an observational cohort study
Abstract
Background: Tuberculosis is a major cause of morbidity and mortality in HIV-infected children, but is difficult to diagnose. We studied mortality and its determinants in antiretroviral treatment (ART)-naive HIV-infected children presenting with suspected tuberculosis.
Methods: In this observational cohort study, HIV-infected children aged 13 years or younger with suspected tuberculosis were followed up for 6 months as part of the ANRS 12229 PAANTHER 01 cohort in eight hospitals in four countries (Burkina Faso, Cambodia, Cameroon, and Vietnam). Children started ART and antituberculosis treatment at the clinician's discretion and were retrospectively classified into one of three groups by tuberculosis documentation: confirmed by culture or Xpert MTB/RIF, unconfirmed, and unlikely. We assessed mortality and associated factors using Kaplan-Meier methods and Cox proportional hazard models. The ANRS 12229 PAANTHER 01 study is registered at ClinicalTrials.gov, number NCT01331811.
Findings: 266 (61%) of 438 children enrolled in the study between April 27, 2011, and May 31, 2014, were ART-naive and included in the analysis (40 had confirmed tuberculosis, 119 unconfirmed tuberculosis, and 107 unlikely tuberculosis). 112·5 person-years of follow-up were available. 154 children (58%) started antituberculosis treatment and 212 (80%) started ART. 50 children (19%) died. Mortality by 6 months was higher in children with confirmed tuberculosis (14 deaths; 2 month survival probability 65·0% [95% CI 50·2-79·8]) compared with unconfirmed tuberculosis (19 deaths; 83·5% [76·8-90·3]) and unlikely tuberculosis (17 deaths; 83·5% [76·3-90·7]; log-rank p=0·0141) and was lower in children with confirmed or unconfirmed tuberculosis who started antituberculosis treatment (p<0·0001 for both). In a multivariate analysis, ART started during the first month of follow-up (hazard ratio 0·08; 95% CI 0·01-0·67), confirmed tuberculosis (6·33; 2·15-18·64), young age (5·90; 2·02-17·19), CD4 less than 10% (2·63; 1·25-5·53), miliary features (4·08; 1·56-10·66), and elevated serum transaminases (4·40; 1·82-10·65) were all independently associated with mortality.
Interpretation: In our cohort, mortality was high in the first 6 months after suspicion of tuberculosis in ART-naive children. ART should be started early, particularly in children with factors associated with high mortality. Documented or empirical tuberculosis treatment decision should be accelerated to reduce mortality and allow early ART initiation.
Funding: ANRS and Fondation Total.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Comment in
-
Preventing tuberculosis-related death in children with HIV.Lancet HIV. 2018 Feb;5(2):e62-e64. doi: 10.1016/S2352-3018(17)30208-4. Epub 2017 Nov 23. Lancet HIV. 2018. PMID: 29174611 No abstract available.
Similar articles
-
Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age.Cochrane Database Syst Rev. 2014 May 22;2014(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. Cochrane Database Syst Rev. 2014. PMID: 24852077 Free PMC article.
-
Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age.Cochrane Database Syst Rev. 2012 Jul 11;(7):CD004772. doi: 10.1002/14651858.CD004772.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2014 May 22;(5):CD004772. doi: 10.1002/14651858.CD004772.pub4. PMID: 22786492 Updated.
-
Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.Cochrane Database Syst Rev. 2010 Mar 17;2010(3):CD008272. doi: 10.1002/14651858.CD008272.pub2. Cochrane Database Syst Rev. 2010. PMID: 20238364 Free PMC article.
-
Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children.Cochrane Database Syst Rev. 2022 Sep 6;9(9):CD013359. doi: 10.1002/14651858.CD013359.pub3. Cochrane Database Syst Rev. 2022. PMID: 36065889 Free PMC article.
-
Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.Cochrane Database Syst Rev. 2016 Dec 10;12(12):CD004246. doi: 10.1002/14651858.CD004246.pub4. Cochrane Database Syst Rev. 2016. PMID: 27943261 Free PMC article.
Cited by
-
Patterns and Cofactors of Polyfunctional Mycobacteria-Specific T-Cell Response Restoration Following 6-Month Antiretroviral Treatment in Children With HIV.J Infect Dis. 2025 Apr 15;231(4):957-966. doi: 10.1093/infdis/jiae630. J Infect Dis. 2025. PMID: 39693245
-
Long-Term Outcomes and Risk Factors for Mortality in a Cohort of HIV-Infected Children Receiving Antiretroviral Therapy in Vietnam.HIV AIDS (Auckl). 2020 Nov 24;12:779-787. doi: 10.2147/HIV.S284868. eCollection 2020. HIV AIDS (Auckl). 2020. PMID: 33262660 Free PMC article.
-
Empirical treatment against cytomegalovirus and tuberculosis in HIV-infected infants with severe pneumonia: study protocol for a multicenter, open-label randomized controlled clinical trial.Trials. 2022 Jun 27;23(1):531. doi: 10.1186/s13063-022-06203-1. Trials. 2022. PMID: 35761406 Free PMC article.
-
Pediatric Tuberculosis: A Review of Evidence-Based Best Practices for Clinicians and Health Care Providers.Pathogens. 2024 Jun 1;13(6):467. doi: 10.3390/pathogens13060467. Pathogens. 2024. PMID: 38921765 Free PMC article. Review.
-
Predictors of mortality among TB-HIV co-infected children attending anti-retroviral therapy clinics of selected public hospitals in southern, Ethiopia: retrospective cohort study.Arch Public Health. 2022 Jan 4;80(1):11. doi: 10.1186/s13690-021-00713-1. Arch Public Health. 2022. PMID: 34983618 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous